Oncology & Cancer

FDA approves CAR T therapy for large B-cell lymphoma

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...

Oncology & Cancer

ASH: Anti-CD19 CAR T-cell Tx beneficial in B-cell lymphomas

(HealthDay)—Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and autologous T cells that express a CD19-directed CAR (CTL019) are effective for refractory B-cell ...

Oncology & Cancer

PFS up with obinutuzumab-based Tx in follicular lymphoma

(HealthDay)—For patients with follicular lymphoma, obinutuzumab-based immunochemotherapy is associated with longer progression-free survival than rituximab-based therapy, according to a study published online Oct. 4 in ...

page 1 from 5